Hit enter to search or ESC to close
Neon Mind
Menu
  • No menu assigned
  • Menu
Press Release

NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial

Press Release

NeonMind Submits Applications to Health Canada for Product Formulas to Support Cognitive and Immune Function and to Fight Stress

Press Release

NeonMind Appoints Robert Tessarolo as President and Chief Executive Officer

Press Release

NeonMind Lists on the Frankfurt Stock Exchange (FSE: 6UF)

Press Release

NEONMIND APPOINTS DR. FRANK RUSSO TO LEAD MUSIC-BASED PROGRAM

Press Release

NEONMIND ENGAGES DR. C. LAIRD BIRMINGHAM FOR OBESITY CLINICAL TRIAL

Press Release

NeonMind Appoints Trevor Millar as Chief Psychedelic Officer

Press Release

NeonMind Commences Trading Under CSE Ticker Symbol “NEON”

Press Release

NeonMind Announces Closing of Oversubscribed Initial Public Offering and Exercise in Full of the Agent’s Over-Allotment Option

  • Investors
  • Shop Coffees
  • Subscribe
Investor Deck

©2021 NeonMind Biosciences Inc.

  • 01Our Focus
  • 02News
  • 03Team
  • 04Investors
  • 05Contact Us
  • 06Subscribe
Shop Coffee

©2020 NeonMind Biosciences Inc.